Endonovo Therapeutics (ENDV) Non-Current Assets (2016 - 2023)
Endonovo Therapeutics has reported Non-Current Assets over the past 13 years, most recently at $780260.0 for Q3 2023.
- Quarterly results put Non-Current Assets at $780260.0 for Q3 2023, down 45.33% from a year ago — trailing twelve months through Sep 2023 was $4.1 million (down 38.74% YoY), and the annual figure for FY2022 was $1.3 million, down 33.83%.
- Non-Current Assets for Q3 2023 was $780260.0 at Endonovo Therapeutics, down from $941988.0 in the prior quarter.
- Over the last five years, Non-Current Assets for ENDV hit a ceiling of $3.7 million in Q1 2019 and a floor of $780260.0 in Q3 2023.
- Median Non-Current Assets over the past 5 years was $2.2 million (2021), compared with a mean of $2.2 million.
- Biggest five-year swings in Non-Current Assets: fell 14.97% in 2019 and later plummeted 45.33% in 2023.
- Endonovo Therapeutics' Non-Current Assets stood at $3.2 million in 2019, then decreased by 20.27% to $2.6 million in 2020, then fell by 25.32% to $1.9 million in 2021, then crashed by 33.83% to $1.3 million in 2022, then plummeted by 38.34% to $780260.0 in 2023.
- The last three reported values for Non-Current Assets were $780260.0 (Q3 2023), $941988.0 (Q2 2023), and $1.1 million (Q1 2023) per Business Quant data.